NovoCure Ltd (NVCR) Q2 2026 Earnings Call Transcript

Good day, and welcome to Novocure's second quarter 2026 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question, you will need to press star-1-1 on your touchstone telephone. Please note this call is being recorded. I would like to turn the call over to Adam Dainey, Head of Investor Relations. Please go ahead.

Good morning. And thank you for joining us to review Novocure's second quarter 2026 performance. I'm joined on the phone today by our Executive Chairman, Bill Doyle, CEO, Frank Leonard, Chief Innovation and Medical Officer, Ori Weinberg, and CFO, Christoph Brockman. For your reference, slides accompanying this earnings release can be found on our website, www.novacure.com, on the Investor Relations page, under Quarterly Results. Before we start, I would like to remind you that our discussions during this conference call will include forward-looking statements and actual results could differ materially from those projected in these statements. These statements involve a number of risks and uncertainties, some of which are beyond our control and are described from time to time in our SEC filings. We do not intend to update publicly any forward-looking statement except as required by law. Where appropriate, we will refer to non-GAAP financial measures to evaluate our business, specifically adjusted EBITDA, a measure of earnings before interest, taxes, depreciation, amortization, and share-based compensation. We believe adjusted EBITDA is an important metric as it removes the impact of earnings attributable to our capital structure, tax rate, and material non-cash items, and best reflects the financial value generated by our business. We do not provide forward-looking guidance for adjusted EBITDA on a gap basis due to the inability to predict share-based compensation expenses contained in the reconciled gap measure, net income, without reasonable efforts. Reconciliations of non-gap-to-gap financial measures are included in our press release, earnings slides, and our Form 10-Q filed with the SEC today. These materials can also be accessed from the Investor Relations page of our website. Following our prepared remarks this morning, we will open the line for your questions. I will now turn the call over to our Executive Chairman, Bill Doyle. Thank you, Adam.

This morning, we reported our second quarter 2026 results, and I am pleased to say this was our strongest commercial quarter to date. With record net revenues and active patients on therapy, we continued to build on the momentum of the first quarter and have also made meaningful progress on our path to profitability. I will begin this morning with a review of our commercial results. Frank will then provide an update on our clinical strategy, Christoph will conclude our prepared remarks with a review of our quarterly financial performance before we open the line for questions. All three of our approved products contributed to our commercial performance this quarter. Starting with Optune Geo, we finished the quarter with 4,636 active patients on therapy, an increase of 11% year over year. A key driver this quarter was U.S. growth, where active patients increased 8 percent year over year. In recent years, we have implemented a number of strategic and structural changes to our U.S. commercial operations that are now bearing fruit. We also saw double-digit year-over-year growth in Germany, Japan, and in our global markets group. We are pleased with the Optune Pax launch to date. We received 418 prescriptions in the quarter, and 285 Optune Pax patients were on therapy as of June 30. We have successfully completed our early launch objectives to engage, train, and support prescribers who are familiar with Optume Pax from pre-approval clinical presentations of the Panova 3 results. We were encouraged by the adoption of Optume Pax at both academic and community practices. From here, our teams will focus on generating consistent repeat prescriptions and engaging physicians who may be less familiar with the clinical data supporting use of Optume PAX. To close on the U.S. Optum PAX launch, I note that our interactions at this year's ASCO conference confirmed that the Panova 3 survival data is viewed as important and relevant for patients with locally advanced pancreatic cancer. Earlier this month, we received CE mark for Optum PAX for the treatment of adult patients with locally advanced pancreatic cancer of exocrine origin, concomitant with gemcitabine and nabpaclitaxel, in accordance with local guidelines. We have since finalized labeling and registration in Germany and begun certifying prescribers. The reference to local guidelines in our label reflects the fact that nabpaclitaxel is not approved for locally advanced pancreatic cancer at the EU level, whereas nabpaclitaxel is recommended for use in the country-level clinical guidelines of many European countries. Turning to Optum Lua, we finished the period with 207 patients on therapy. The early signals from the Japan launch are consistent with our previously stated expectation that clinical practice patterns in Japan align more closely with our label than other Optum Lua markets. As a reminder, we received national reimbursement in March and began certifying physicians soon after. As of June 30, we had 64 Optum Lua patients on therapy in Japan. We are still in the early phase of the launch in Japan. While the established reimbursement policy covers all Japanese patients, Additional contracting is required at each treatment site. As more hospitals and prescribers are contracted in the coming quarters, we expect Japan to be our leading Optunlua market. Finally, the FDA review of Optunmaya for the treatment of brain metastases from non-small cell lung cancer remains on track for a Q4 decision. Earlier this month, the NCCN updated guidelines for the treatment of brain metastases and included Optune Maya as a Category 2A recommended treatment option for patients with limited brain metastases from non-small cell lung cancer without targetable mutations. We are pleased that the NCCN opted to include TT Fields therapy and believe this will be helpful for a future launch pending FDA approval. With three devices launched and a fourth under FDA review, we are in the favorable position of having multiple products contributing to growth in the coming years. We are focused on achieving the regulatory and market access milestones required to bring tumor treating fields therapy to more cancer patients in more regions as quickly as possible. Frank will now walk through some of the updates to our clinical programs.

Thank you, Bill. We are entering a new phase of clinical development at Novocure. Historically, our clinical strategy has focused on areas of significant unmet need and opportunities to establish TT fields in new cancer types. With three products approved and one under FDA review, we are shifting that mandate to focus on strengthening our market position and broadening labels. Our near-term focus is pancreatic cancer. Optune Pax is currently approved for first-line use together with gemcitabine and nabpaclitaxel in locally advanced pancreatic cancer, which is classified as stage 3. Our primary goals are to solidify our position in the locally advanced setting and explore TT field therapy use in earlier stages of the disease where the tumor is or may be resectable. We are designing additional sponsored trials to support label indication in both locally advanced disease and earlier stages of pancreatic cancer. We are also in active negotiations with industry partners to explore the concomitant use of TT field therapy with either RAS inhibitors or other innovative approaches to treat pancreatic cancer in pilot trials focused on feasibility and early efficacy signals. This approach is grounded in extensive discussions with prescribers, key opinion leaders, and the preclinical results showing promising signals from the concurrent use of TT fields and KRAS inhibitors. We believe this focus will best position Optune PACs to remain integral to the evolving standard of care in pancreatic cancer. In addition, we are preparing to open an IDE trial for concurrent use of TT T-Fields therapy and diraxin-rasib following its expected FDA approval. The intent of this trial will be to generate safety and feasibility data quickly and provide physicians with clinical data to evaluate how best to use the two therapies moving forward. We do not intend to open a registrational trial in metastatic pancreatic cancer at this time. We are also continuing our efforts to increase the data-supporting use of T-T-Fields in our approved indications for GBM and non-small cell lung cancer. The Keynote D58 trial is on track to complete enrollment by year-end with database lock and top-line readout approximately two years later. Keynote D58 is a phase three trial exploring the addition of pembrolizumab to the current standard of care of TT Fields therapy and maintenance chemotherapy for GBM. Turning now to non-small cell lung cancer, Lunar II is a phase three trial exploring first-line use of TT Fields therapy, pembrolizumab, and platinum-based chemotherapy for the treatment of metastatic disease. We have initiated several changes to this trial with the goal of lowering total trial costs and accelerating the pace of trial completion. The first step was the optimization of our clinical footprint. We are in the process of reallocating clinical resources to high engagement, high enrolling sites and discontinuing the trial at lower enrollment sites. The second One step is to amend the protocol to streamline the trial's primary endpoints with the goal of reducing the patient's sample size. We believe these changes will cut the total spend on LUNR by approximately $90 million with the savings allocated to pancreatic cancer programs. The refreshed focus of our clinical program should be beneficial on several fronts. First, it will enable faster data generation, address potential data gaps, and provide flexibility to remain ahead of the evolving standards of care. Second, these changes allow us to balance ongoing R&D investment at our current level with our goal of reaching profitability in the coming years. Finally, I want to express my thanks to all of the NovaCure employees for their hard work and dedication to achieving our goals. We have started the launch of Optume Pax, refocused our R&D efforts, and implemented operating expense discipline to ensure we have a clear path to profitability. We made great strides towards these goals in Q2, and I am incredibly proud of what the team has achieved overall this year. I'll now pass the call to Christoph to review our financial performance in the quarter.

Thank you, Frank, and thank you all for joining us this morning. We continued our strong start to the year in Q2. Net revenue in the second quarter was $184 million, an increase of 16% year-over-year. The increase was driven by Optune Geoactive patient growth of 11% year-over-year, as well as increased contributions from Optune Lua and Optune Pax of $5.4 and $1.6 million, respectively. We benefited from $3 million in one-time items, driven by increased approval rates and age claims in Germany, lower annual deductible reset impact in the US, and performance improvements in France. The exchange rate impact versus Q2 of last year was overall immaterial with some benefits in Europe being offset by the Japanese yen. Based on the strength of our commercial performance in Q2, we are updating our full year revenue guidance to a range of 710 million to 725 million dollars representing 8 to 11 percent growth. We're also updating our guidance range for combined revenue from Optium Lua and Optium Pax to $20 to $30 million for the year. Gross margin in the quarter was 78% compared to 74% in Q2 of 2025. This was primarily due to a tariff refund of $5 million as well as lower array costs due to improved utilization and manufacturing efficiencies. We expect quarterly gross margins to remain in the mid-70s through year-end 2026 as we bring more of tuned Pax patients on therapy prior to establishing broad reimbursement. Research and development costs in the quarter were $51 million, a decrease of 8% compared to the same period in 2025. The change was primarily driven by lower direct trial costs associated with phase 3 trials that have concluded, as well as lower costs associated with the LUNA-2 trial. With the redesign of our LUNA-2 trial, we are confident that we can keep R&D costs at or below current levels in the future while being able to invest in our clinical development aspirations as outlined by Frank earlier. Sales and marketing expenses in Q2 were $62 million, up 8% from Q2 2025. The increase was primarily due to costs associated with the ongoing launch of Optum Pax in the US and Optum Lua in Japan. G&A costs in the quarter were $40 million, a decrease of 9% from the same period last year. This was primarily driven by a lower share-based compensation expenses. Our net loss for the quarter was 16 million dollars compared to 40 million dollars in Q2 2025. Loss per share in the quarter was 13 cents. Adjusted EBITDA in the quarter was 11 million dollars compared to negative 10 million dollars in the second quarter of 2025. We are updating our full-year adjusted EBITDA guidance this morning to a range from 0 to 15 million dollars. Our cash and investment balance as of June 30th, 2026 was 441 million dollars. We are unambiguous in our enterprise-wide focus on reaching profitability in the coming years. This includes driving strong revenue growth as well as diligent expense management and the pursuit of cost-optimizing projects like the Luna 2 trial. In recent years, we have made the infrastructure investments required to support the commercial operations of Optune Geo, Lua, PAX, and Maia. As these launches continue to gain momentum and net revenue continues to grow, we expect to see significantly greater leverage across the P&L, providing a tailwind to profitability. The first milestone in our path to profitability is to reach break even on an adjusted EBITDA level, which we now plan to achieve for the full year of 2026. Thank you all for joining us this morning. We'll now open the line for Q&A.

Thank you. Ladies and gentlemen, as a reminder to ask the question, please first start 1-1 on your telephone, then wait for your name to be announced. To withdraw your question, please first start 1-1 again. Please stand by while we compile the Q&A roster. Our first question comes from the line of Ajay Kumar with Evercore. Your line is open.

Hi, guys. Thank you for taking my question. Congrats on a nice print here. Maybe my first one on this patriotic launch. Strip volumes up sequentially in the triple digits. Active patients up north of 200%. I guess, can you give us a little bit more flavor on where is this growth coming from? How many docs are prescribing currently? Is this coming from existing physicians or new physician ads? And when you think about that sequential trajectory, it looks really strong. Is this sustainable here for back half? Like, how should we think about PANC launch, continued adoption, if you will, for the back half?

Hi, Vijay. Thank you. This is Frank. Appreciate the question, and we'll start by noting that we are pleased with the launch in pancreatic cancer. As a reminder, for Q1, we really only had one month of activity. So in looking from Q1 to Q2 on pure statistics, it is absolutely a strong quarter in terms of statistical growth. But to give it the color and the context that you asked about, I would say that we have been first and foremost very pleased with our ability to interact both at community practices as well as academic practices. And so in terms of the sites that we're training and certifying, we're seeing that breadth across different types of providers we are not giving context right now on the total number of certifications but i would say that from a color perspective we've been able to get access to the practices and to ensure that we can get certifications done quickly we are right now looking at about half half of our prescriber base has already become a repeat prescriber with the other half having having initiated treatment once and you know we think that at this point in the launch is pretty common. We have a big set of physicians who are interested, and as with any new modality, there's that interest to get it on one patient to try. And then the challenge for us as we move forward to answer the part of the question about the future, as we look ahead, one of our major focuses for Q2, Q3, pardon me, is that we need to push that number of repeat prescribers up and go from trying Optune to Optune is integrated in my practice.

That's helpful, Frank. And maybe one more on PAX. I think I heard you say we'll start an IDU trial for TTF plus RAS inhibitors. I'm curious, when you look at these early data that you have, and when you compare to early data that you had in other indications, right, what gives you the confidence here on TTF plus RAS, we're seeing a positive signal that gives you the confidence to start this IDA trial. And I think I've heard you mention this is going to be an IDA, but not a registrational study, right? Like, why is this an IDA, not a registrational trial? And at some point in the future, do we need a registrational study for TTF plus RAS?

Yes. Thank you. So, to highlight our – what we've announced in this call is that we do see interest and, in fact, a need to open a trial where physicians can use TT fields plus a RAS inhibitor. The fastest way to do that is after Duraxone RASib has its FDA approval, we can do that through an IDE trial. As you noted, and as I'll reemphasize, you know, we are opening this trial in order to look at safety and feasibility signals, because these are both, you know, two new modalities, and we are really looking at it from that perspective of safety and feasibility, and we are not in metastatic disease looking to move towards a registrational trial or, indeed, to a larger trial with hard efficacy endpoints. I'll let Ori speak in just a moment to some of the preclinical rationale. But what I will say is that as we spend time at ASCO, and in fact, as we've interacted with our prescribers, we do just see the clinical interest in answering the question of how can you use these two therapies together? And so we believe we need to work as fast as possible to begin addressing that question. Ori?

So, from a scientific perspective, we have been able to publish already that tt-field therapy in the preclinical setting led to the downregulation of CEMIC, which is a master regulator of cancer cell proliferation and metastasis. And CEMIC, being downstream of RAS in many cases, has the possibility of influencing the overall silencing of this pathway, leading when using TTFIL therapy concomitantly with KRS inhibitors to an overall greater and maybe even synergistic effect. And this has been reported through our preclinical results and has actually been reproduced also by Mayo Clinic and independent research that was conducted by their research team. These findings were published in the recent AACR conference. Now, on top of the opportunity to get the clinical data as soon as possible by utilizing and using the fact that Keras inhibitors are primarily going to be approved in metastatic disease first, this also secures and promotes our communication and advancement towards partnerships with other commercial companies in this field, and we are working in this direction too.

Great. Thank you, guys.

Thank you. Please stand by for our next question. Our next question comes from the line of Jason Vintnar with Piper Sandler. Your line is open.

Hey, good morning, everyone. Congrats on another nice quarter here. I also wanted to start on the pancreatic indication like BJ. Frank, can you talk a bit more about prescribing patterns, patient acceptance, and conversion from Rx to active patients, and particularly on that Rx conversion to active patients? Are we at a point where we can begin to use the experience thus far to inform how we think about the model and future conversion?

Thank you, Jason. In terms of the prescriber patterns, as I mentioned earlier, right now we are seeing about 50-50 of prescribers who have tried it once and those who have used it multiple times. We expect over the coming quarter to continue broadening out the number of prescribers, But, you know, we will focus in this quarter on driving up the repeat prescribers because it's, you know, if you think about the effort on our side and the effort on the physician side to, you know, to use the therapy for the first time, once you've cleared that hurdle, it's really a time to consolidate the engagement with the practice and drive up the volume. And I say that because as I looked at our prescribing patterns for this quarter, one thing that does jump out is that we have, in terms of our highest volume sites, for the first time, it's both a mix of community and academic practices, whereas I think as you know, in the past, we've sometimes had challenges getting into these large academic practices. We're not seeing that this time around either. So, you know, to sum up on prescribing patterns, I think it was a good effort in the first two quarters of the launch to get to the physicians who are interested. It was a good effort to get, you know, as many people prescribing as possible. We're seeing repeat prescribing in 50% of the population, and we're seeing access to academic sites in a way that we haven't seen before. In terms of modeling fill rate or conversion rate from Rx to start, I would say because it's a launch and because it was a first full quarter, I wouldn't begin trying to glean specific statistics from the numbers. I think you'll need a little bit more time from a sample size perspective.

Okay. Maybe one follow-up, and I've got one for Christophe too here. I'll just pack them both together. But on the fill rate, conversion rate, is there a reason to think PAX is different from GEO longer term, just anything structurally or about that indication that you think we should be using or assuming different fill rates? And then, Christoph, the business is definitely establishing a better revenue execution pattern here, another guidance raised second of the year. I guess the question, though, even with the raise, the high end of the revenue guide implies a growth decel and absolute revenue that's on par with what you just put up in 2Q. So maybe help me, why is that the right level? It seems like we should be even higher than where you took things.

Jason, on the fill rate question, I don't think I would draw a direct connection to GBM or a reference point yet. But the patient population, just based on the chemo regimens, it's, you know, we really do, I think even, you know, we would say this to ourselves, we need a little bit more time to really see where the fill rate settles. What I would say, though, is that it's a shorter time between prescription and start than what we typically see in GBM, and we do see really motivated patients. So, I don't want to draw a conclusion one way or the other, but I also don't want to raise any alarms that we think it's going to be very low, I guess is what I would say.

And thank you, Jason, for the revenue question. So maybe first as background, we increased the net revenue guidance from 690 to 710 million to today, 710 to 725 million, which would be a range of 8 to 11 percent in growth. And the midpoint is W2 growth, 10 percent growth. So we're very happy, based on the strong performance in Q2, to be able to what I would call substantially raise our revenue guidance. Now, with regards to your point on the high end of the revenue guidance is basically in line with the Q2 results. Two answers. So one is we called out 3 million in one-time items in Q2. And the other one is I would say Q2 was really an exceptional quarter where we had sales of 10 million more than in the prior quarter or 9 million if you compare to Q4. So, really, we would say the stars aligned in Q2, particularly also with having a very strong growth in the U.S., 8% year-over-year active patient growth in the U.S., and you know that that has a fairly substantial impact on revenue.

So, long story short, we are very focused to achieve an outcome that is towards the higher end of our guidance range, but we also wanted to respect that we had a fantastic quarter in Q2. okay thank you both appreciate it thank you our next question comes from the line of larry biegelson with wells fargo your line is open oh good morning thanks for taking the question and congrats on a nice quarter um so um i wanted to ask about lua uh in japan which was strong in in the second quarter um was there a pent-up demand and how should we think about that going forward It does look like when I, Christophe, when I look at the guidance for Lua and PAX, it almost seems to imply, you know, Lua revenues flat in the second half of the year, you know, if PAX is growing and had one follow up.

Yeah, so maybe first on Lua and Japan in general, we are very pleased with the launch and we had the hypothesis that our data from LUNA overlaps better with the standard of care in Japan than in other markets and that I think has proven to be the case. Now, we do expect substantial, sequential increase in patients. I would say, particularly with LUAR, the duration in the clinical trial was about four months. So, growth will at some point get more difficult, but we do expect sequential growth. And with the revenue guidance, I would just say for the new products, it's very difficult to project.

And, yeah, maybe the other point for Japan specifically is we have national reimbursement, but we have to work through a contracting process, hospital by hospital. and while we do make significant and have made significant progress in q2 that's a gating item and it's just something that the team will need to continue to work through that's helpful and then maybe frank uh back to uh up to impacts once the rest inhibitors are approved which is you know expected shortly do you think they'll be used off label in earlier stages of pancreatic cancer and What are clinicians telling you about their willingness to prescribe, you know, both the RAS inhibitor and TTF in the same patient before you complete this IDE you talked about today? Thank you.

Thanks, Larry. Yes, I mean, I think just as a company that's committed to innovation, I'll start by noting that we're very happy that there's going to be another therapy approved for pancreatic cancer patients. You know, even with the success of diraxin or acid, we're still talking about median overall survival of approximately 13 months in their indication. And so, we think there's still more to be done. And as with all of our indications, you know, we think that tumor-treating fields is particularly capable of being a backbone therapy as new medical therapies come to market due to our low toxicity profile, non-systemic toxicity. Specifically, what we're hearing from our KOLs and our prescribers is that there is an interest in understanding how to use tumor-treating fields with RAS inhibitors. I'll note, as you know, Larry, we are approved in locally advanced pancreatic cancer, and they will be coming to market in second line, stage four, so later stage and in the second line of treatment. And I think it's too early to predict an exact impact of what will happen in the real world because there's payer dynamics that will be at play too in addition to clinical dynamics over how RAS inhibitors are introduced. But I think, you know, we're very confident based on everything we've heard today that within locally advanced pancreatic cancer, our indication that, you know, there's strong interest in tumor-treating fields And whether it's RAS inhibitors or new agents, we'll have to continue studying tumor-treating fields with them and building that evidence for clinicians.

All right. Thanks so much.

Our next question comes from the line of Jess Fye with J.P. Morgan. Your line is open. Hey, guys.

Thanks for taking your question. Another one on Optune packs. I was trying to infer from your comments about the mix of, you know, one-time prescribers versus repeat prescribers so far, but I figured maybe just to ask you directly, like, what's the total number of prescribers who are sourcing those, you know, 418 PACS scripts in the quarter?

Thank you. Thanks, Jess. We, you know, we haven't given the specific number of certified prescribers, and we think, you know, we've talked about whether or not to give that number. There's some nuances there because it's a different, you know, not all prescribers are the same. Some are super high volume. Some are a doc who mostly does lung cancer, but occasionally does pancreatic cancer. But what I can say is that the range of prescriptions within a practice right now ranges between one, they've tried it once, and some practices have written more than some doctors have written more than 10 prescriptions. And that's really why when we look at this 50% of prescribers who have only written one prescription, we see tremendous room for growth if we can drive them to that higher end, that point at which tumor treating fields, opt-in packs is really integrated into their routine clinical practice.

Thank you.

Please stand by for our next question. Our next question comes from the line of Kevin DeJeter. with Lindenburg-Fallman. Your line is open.

Hey, great. Yeah, thanks for taking our questions. I'll just add another one on Pox.

Can you talk a little bit about the go-to-market strategy in Germany and just kind of how we should think about, you know, the dynamics there for initial uptake and payment and reimbursement? Thank you.

Thank you, Kevin. Yeah, I'll comment at a high level about the launch in Germany, and then I'll turn it over to Christoph to talk about our expectations. So, Germany, much like the United States, allows for case-by-case reimbursement as new products come to market. And so, much as we did in GBM, we are launching the product and then pursuing reimbursement on a case-by-case basis. We are typically, in Germany, what we're going to do is focus on the large national cancer centers. We are rolling out right now already our initial marketing and sales campaigns and really working on that effort to educate the largest cancer centers and begin certifying them. And then from there, we would expect there'll be a build. I think I would highlight that in Germany, we did not have as many of the direct KOLs involved in the trial. And so, there is a bit of an education process that we will have to undertake. But much like in the United States, we've seen a belief in the data that our data from the Panova trial was compelling, is clinically relevant. And so, we're excited for the launch.

And we just have to now work through those those reimbursement hurdles yeah maybe just some some words on the total time so incident rates in western europe are quite comparable to the u.s the time in the u.s on label is 15 000 patients annually and in germany it's about a fourth we expect it to be 4 000 patients on label. And as Frank said, we believe that the build will be at a slightly slower slope than in the U.S., but we're very excited to launch and we have started to do so.

Great. Thank you. Thank you. Our next question comes from the line of Emily Bonar with HC Wainwright. Your line is open.

Sorry to worry. Thanks for doing the question. And congrats on the positive quarter. Maybe also on often times, if you can kind of discuss some of the early trends you're seeing maybe in the initial patients that are getting on therapy, and also any feedback you're getting on prescribers with real-world use of the drug, or sorry, of the therapy. And maybe for a second, you mentioned the combo of TT fields to spratus inhibitors. It sounds like you're looking at mainly the metastatic setting. I was curious if maybe you could also expand this into the locally advanced setting where you're already marketing. Thanks.

Thank you, Emily. I'll start with the second half of the question to just highlight that in our work to open trials with RAS inhibitors, there's two separate activities underway. One is an IDE trial focused on safety and feasibility, and that would be a trial run after diraxan or acid has FDA approval to enable us to do a trial with an FDA-approved drug. That would be within their label of second-line metastatic so that we can run that trial as an IDE trial and be the sponsor. It's just the fastest way for us to gain access to the compound once it's approved. We are also, at the same time, pursuing business development discussions with industry partners to explore earlier stage trials with both RAS inhibitors and some of the newer, more innovative compounds that are being tested in pancreatic cancer. So, it is a both story. It's getting data with Drax and Rasiv as fast as possible and also looking at how we bring these innovative agents along with tumor treating fields to locally advanced pancreatic cancer in earlier stages. And in terms of your question about some initial stories, feedback, I think, you know, there's a couple, kind of two stories I would share. I think one is we've been pleased with our ability to help a wide range of patients in terms of their physical capabilities and the concurrent therapies they may be receiving. You know, what we've learned through this process is that not all pancreatic patients are the same. There's varying levels of disability from the disease, of fatigue from the concurrent therapies, and I think what I'm particularly proud of is that our team has figured out how to, you know, help all those patients, keep them on therapy, and keep them progressing. And, you know, the second thing I would say in talking with several of our KOLs, including one of our top prescribers very recently, we know from the Panova trial that pain-free survival extended by six months for our patients. And we are hearing anecdotes from the physicians who are hearing it directly from the patients that there is an experience of pain-free survival, that there is something happening that's, you know, beyond our ability from the data. We know we can extend overall survival, but for the first time, I'm starting to hear these stories from patients back to their physicians that they can actually feel the pain differently. And, you know, it gives us confidence that we're pulling through that that six-month observed pain-free survival from the trial is, in fact, actually having clinical relevance.

Great. Thank you. Thank you. Ladies and gentlemen, I'm showing no further questions in the queue. I would now like to turn the call back over to Frank Leonard, Chief Executive Officer, for closing remarks.

Thank you. Q2 was an exciting quarter for Novocure. We reached new heights in both active patients and net revenues. We saw another strong quarter of growth in Optune Geo, an exciting introduction of Optune Lua in Japan, and continued the promising launch of Optune Pax in the U.S. In addition to the positive commercial momentum, we have also made significant progress to our objective of returning to profitability, posting a positive adjusted EBITDA result for the first time since 2024. for. It's truly an exciting time for NovoCure as we bring the promise of tumor-treating fields to the more than 5,000 patients on therapy today. To the NovoCure team, thank you for your extraordinary work this year to help so many patients. We look forward to updating everyone on our progress through the remainder of the year. Thank you for joining us this morning.

Ladies and gentlemen, that concludes today's conference call. Thank you for your participation. You may now disconnect.